AB125. The correlation of SRSF1 and survivin in prostate cancer

Objective: To test the expression of serine/arginine rich splicing factor 1 (SRSF1) and survivin [poptosis inhibiting factor (survivin)] in prostate cancer organizations, and study their correlation with the pathological features of prostate cancer, thus put forward the new targets in the treatment of prostate cancer.

Methods: SRSF1, survivin protein was analyzed in 20 prostate tissue samples including prostate cancer and benign prostatic hyperplasia by immunohistochemical SP method. SRSF1, survivin was correlated to pathological features, and both the relevance was analyzed (no related reports at home and abroad).

Results: The positive expression rate of SRSF1 protein in prostate cancer tissue cells was 76.37%±5.06%, significantly higher than that of benign prostatic hyperplasia 11.30%+1.09% (P<0.05); the positive expression rate of survivin protein in prostate cancer tissue cells was 86.93%±3.21%, significantly higher than that of benign prostatic hyperplasia 17.67%±1.99% (P<0.05); SRSF1 and survivin protein expressed in prostate cancer organizations and were positively correlated to pathological Gleason grading, and the second Have significant correlation (P<0.05).

Conclusions: SRSF1 and survivin protein were highly expressed in adenocarcinoma tissue, significantly increased than that of benign hyperplasia of prostate tissue. The positive expression SRSF1 and survivin protein were positively correlated to pathological Gleason grading. The expression of survivin protein was elevated with the expression of survivin SRSF1protein in prostate cancer. Preliminary evidence about the role of SRSF1 may be through up-regulation the expression of survivin, thus promote the occurrence and development of prostate cancer.

Keywords: Prostate cancer; serine/arginine rich splicing factor 1 (SRSF1); survivin